Expert Interview
A Second View: Discussing the VISION-2 phase 3 study of Microline as a potential on-demand treatment for presbyopia
Ticker(s): EYENInstitution: Private Practice
- Optometrist and Medical Director of Vita Eye Clinic (North Carolina).
- Lead investigator on over 30 clinical trials in ophthalmology research to date with a focus on emergency ocular medicine, ophthalmic pathology, diabetic and hypertensive eye disease, glaucoma, co-management of systemic diseases, and updates in pharmacology and pharmacokinetics.
- Author, international speaker, and clinical researcher for novel breakthroughs in ophthalmic drugs; splits his time 50/50 between his primary care patients and research patients.
How many patients do you see monthly with presbyopia?
Added By: c_adminWhat are your thoughts on the data from the VISION-2 study?
Added By: c_adminWhat exactly does the Optejet do to justify an expense greater than eyedroppers?
Added By: c_adminWhat do you believe is the real unmet need here that this specific drug/device combo resolves?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
